Search results
Showing 226 to 240 of 261 results for carcinoma
Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)
This guidance has been replaced by NICE technology appraisal guidance 474.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
This guidance has been updated and replaced by NICE technology appraisal guidance 555.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Discontinued Reference number: GID-TA11421
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
This guidance has been updated and replaced by NICE technology appraisal guidance 849.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
This guidance has been updated and replaced by NICE technology appraisal guidance 432.
In development Reference number: GID-TA11831 Expected publication date: TBC